Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
42.59
-1.89 (-4.25%)
Feb 21, 2025, 4:00 PM EST - Market closed
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Ultragenyx Pharmaceutical stock have an average target of 93.13, with a low estimate of 48 and a high estimate of 140. The average target predicts an increase of 118.67% from the current stock price of 42.59.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 6 | 6 |
| Buy | 9 | 9 | 7 | 7 | 8 | 8 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 14 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $95 | Strong Buy | Reiterates | $95 | +123.06% | Feb 18, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $121 → $136 | Strong Buy | Maintains | $121 → $136 | +219.32% | Feb 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $95 | Strong Buy | Reiterates | $95 | +123.06% | Feb 14, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $118 | Buy | Reiterates | $118 | +177.06% | Jan 22, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $135 → $140 | Buy | Maintains | $135 → $140 | +228.72% | Jan 13, 2025 |
Financial Forecast
Revenue This Year
668.11M
from 560.23M
Increased by 19.26%
Revenue Next Year
914.79M
from 668.11M
Increased by 36.92%
EPS This Year
-5.23
from -6.29
EPS Next Year
-3.05
from -5.23
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 826.4M | 1.2B | 2.1B | ||
| Avg | 668.1M | 914.8M | 1.4B | ||
| Low | 575.3M | 691.1M | 782.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 47.5% | 75.3% | 130.0% | ||
| Avg | 19.3% | 36.9% | 50.9% | ||
| Low | 2.7% | 3.4% | -14.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.83 | -0.66 | 5.78 | ||
| Avg | -5.23 | -3.05 | 0.42 | ||
| Low | -6.98 | -4.87 | -2.86 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.